GlassScriptPhysician profile
Michael X Liu
NPI 1851402721
$8,139.29
in general payments reported to CMS, 2019-2025
62 companies · $467 in 2025
The $467 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,645 · 2020: $834 · 2021: $561 · 2022: $1,127 · 2023: $1,401 · 2024: $1,103 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $949.18 | 2019-2025 | |
| Abbvie INC. | $718.45 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $655.16 | 2019-2021 | |
| Ucb, INC. | $649.61 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $352.97 | 2019-2023 | Vumerity, Spinraza, Plegridy |
| Mdd US Operations, LLC | $297.82 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $246.99 | 2019-2022 | |
| Celgene Corporation | $237.65 | 2023-2025 | Zeposia |
| Amgen INC. | $224.60 | 2019-2022 | |
| Lilly USA, LLC | $222.39 | 2019-2025 | Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $220.53 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $201.58 | 2019-2024 | |
| Allergan, INC. | $175.21 | 2019-2020 | |
| Genentech USA, INC. | $157.30 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Neurelis, INC. | $156.45 | 2023-2025 | Valtoco |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.